Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Helius Medical Technologies, Inc. has announced that Aetna Healthcare has authorized payment for the PoNS Device at an out-of-network negotiated price of $18,350, making Aetna the third major ...

The PoNS device is a non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece to improve balance and gait. It is FDA-authorized as a short-term treatment for ...

Depending on the individual’s deductible and out-of-pocket costs, this claim may not result in an immediate PoNS Device sale. About the PoNS Device and PoNS Therapy The Portable Neuromodulation ...

Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network ...

CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers ...

Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement ...

NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of ...